Paul Tudor Jones Moon Lake Immunotherapeutics Transaction History
Tudor Investment Corp Et Al
- $15.5 Billion
- Q1 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 31,411 shares of MLTX stock, worth $1.25 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
31,411
Previous 30,154
4.17%
Holding current value
$1.25 Million
Previous $1.82 Million
13.4%
% of portfolio
0.01%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding MLTX
# of Institutions
135Shares Held
56MCall Options Held
379KPut Options Held
402K-
Bvf Inc San Francisco, CA21.8MShares$864 Million32.73% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$337 Million24.56% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.58MShares$102 Million1.56% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.31MShares$91.7 Million0.02% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.28MShares$90.7 Million0.23% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $1.47B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...